开放标签 英语是什么意思 - 英语翻译

• open-label
• an open label
• open label
• an open-label

在 中文 中使用 开放标签 的示例及其翻译为 英语

然而这项研究是开放标签的，并且没有包含对照组。
However, this study was open-label and did not contain a control group.

该研究的局限性在于其开放标签的观察设计。
Limitations: This study has an open label observation design.

该研究是一项开放标签研究，正在.
This study is an open label study.

该研究的部分开放标签试验仍在进行中。
An open label extension of this study is ongoing.

这项开放标签试验预计将于2020年初启动。
This open label trial is expected to begin in early 2020.

开放标签可控研究”.
An Open Label Non-Randomized Controlled Study".

ENDEAVOR是一项随机、开放标签III期.
MonarchE is a phase III, open label trial.

首先，这是一个开放标签的临床试验。
This is an open label clinical study.

首先，这是一个开放标签的临床试验。
It is actually an open label clinical trial.

开始和结束标签也被称为开放标签和闭合标签。
Start and end tags are also called opening tags and closing tags..

另一项开放标签研究发现，每天服用三个月经周期的250mg缓释镁可显着减轻PMS症状（16.
Another open-label study found that 250 mg modified-release magnesium, taken daily for three menstrual cycles significantly reduced PMS symptoms(16).

在试验的随机阶段之后是一个为期18周的开放标签期，其中所有患者都接受了罗沙司他治疗；.
The randomized phase of the trial was followed by an 18-week open-label period in which all the patients received roxadustat;

DNDi展开STORM-C-1开放标签试验以评估候选药物ravidasvir与sofosbuvir联用的疗效、安全性、耐药性和药物动力学。
DNDi conducted the STORM-C-1 open label trial to assess the efficacy, safety, tolerance and pharmacokinetics of the drug candidate ravidasvir combined with sofosbuvir.

Lynparza的批准是基于随机、开放标签、III期OlympiAD试验，该试验评估了Lynparza相较化疗的结果。
The approval is based on data from the randomised, open-label, Phase III OlympiAD trial, which tested Lynparza vs chemotherapy.

本研究的一个开放标签部分证明了Myobloc在随后的给药期超过1年的安全性和有效性。
An open-label portion of this study demonstrated MYOBLOC's safety and efficacy over time at subsequent dosing sessions for over 1 year.

Firazyr儿科适应症的获批，是基于一项开放标签、非随机、单组研究，该研究入组了32例儿科HAE患者。
The use of Firazyr in paediatric patients was studied in an open label, non-randomised single-arm study, involving 32 paediatric patients with HAE.

目前，杰特贝林正在开展一项长期开放标签扩展研究，预计将在今年晚些时候完成。
A long-term open label extension study is ongoing and is expected to be completed later this year.

Lynparza的批准是基于随机、开放标签、III期OlympiAD试验，该试验评估了Lynparza相较化疗的结果。
The approval was based on data from the randomised, open-label, Phase III OlympiAD trial which investigated Lynparza versus physician's choice of chemotherapy.

完成该项研究的所有患者将参与一项开放标签扩展研究。
A significant number of patients enrolled in the study are participating in an open-label extension study.

该分析包含来自六项临床试验的患者（n=1,126），即TOMORROW试验、两项INPULSIS®试验及随后进行的开放标签扩展试验3。
The analysis included patients from six clinical trials(n=1,126), including TOMORROW, the two INPULSIS trials, and their open-label extension studies.

这些病人在完成这期临床试验后，会进入开放标签、长期的安全性扩展研究。
After completion of the study, patients will be offered the opportunity to enroll in an open-label, long-term safety study.

之后，患者进入开放标签扩展期，所有患者每6个月一次接受一次inebilizumab治疗。
Patients were subsequently placed into open label extension in which all patients received inebilizumab every 6 months.

阶段1/2研究的B部分正在进行给药，符合条件的患者正在过渡到开放标签扩展（ole）研究。
Dosing in Part B of the Phase 1/2 study is ongoing and eligible patients are transitioning into an open-label extension(OLE) study.

Revcovi的获批，是基于2项多中心、开放标签临床研究的结果。
Revcovi's approval is based on the results of two multicenter, open-label clinical studies.

这些研究品谷了Nplate在ITP成人患者中的安全性和有效性，其中包括2项长期开放标签扩展研究。
The submission is supported by nine studies evaluating the safety and efficacy of Nplate in adults with ITP, including two long-term open-label extension studies.

抗病毒活性的TMC435单药治疗中病人感染丙型肝炎病毒基因型2到6：TMC435-C202，国际投资协定，开放标签研究阶段。
Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study.

RESTART是一项在英国122家医院进行的前瞻性、随机、开放标签、盲法终点和平行组临床试验。
The REstart or STop Antithrombotics Randomised Trial(RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK.

开放标签III期试验显示，与曲妥珠单抗相比，T-DM1可使侵袭性疾病复发或死亡的风险降低50％。
The open-label phase III trial showed that T-DM1 reduced the risk of invasive disease recurrence or death by 50% compared with trastuzumab.

VTvTherapeutics将会停止目前涉及azeliragon的临床研究，包括开放标签扩展研究和STEADFAST研究的b部分。
VTv Therapeutics said it will discontinue current clinical studies involving azeliragon, including the open-label extension study and Part B of the STEADFAST study.

名患者，年龄46-91岁，被纳入开放标签，非随机研究。
Fifty patients, aged 46- 91 years, were enrolled in the open-label, nonrandomized study.